August 6, 2022, SHANGHAI /— Using modulation of the epigenetic genome, Epigenic Therapeutics Co., Ltd., a cutting-edge biotechnology company committed to creating the next generation of gene editing therapy for a wide range of disorders, today announced it has raised USD 20 million in Series Angel and Pre-A funding. 

Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund, and TigerYeah Capital contributed to the Series Pre-A fundraising. FountainBridge Capital, an angel investor, is also involved.

The financing’s proceeds will grow knowledge and capabilities, support early-stage clinical trials, and validate developments of the Company’s patented epigenetic editing in non-human primates.

Bob Zhang, co-founder and chief executive officer of Epigenic Therapeutics :

“We are able to deepen our understanding of the precise regulation of the epigenetic genome and unlock its potential as a treatment for a variety of diseases with the help of our scientific co-founders and advisors. With the money, we’ll be able to keep growing our staff and our capabilities, test the technological platform in an animal model, and move more quickly toward clinical development for our top product.”

Michael Xue, Managing Director of Morningside Venture, offered his opinion:

“In comparison to other developers of gene editing therapies, Epigenic Therapeutics has a unique position. We are happy to have invested in Epigenetic Therapeutics since we think this business has a strong platform for continued research and development of precision genome medicine, which will help many people.” 

More about the company:

A cutting-edge biotechnology business called Epigenic Therapeutics is committed to creating next-generation gene editing therapies that use epigenetic genome regulation to treat various disorders. The Company, established in 2021 by eminent scientists to identify new gene editing technologies and create gene editing medicines, is currently developing several product candidates for treating ophthalmic, neurodegenerative, metabolic, and uncommon disorders.

The patented technological platform of Epigenetic Therapeutics uses its own artificial intelligence (AI) algorithms to investigate and find an optimum CRISPR-Cas component to control target gene(s) or regulate the expression of one or more genes simultaneously without altering the DNA sequence. 

Compared to competing technologies, the technology can avoid possible risks associated with DNA cleavages, such as off-target effects, short half-lives, and complex patient compliance concerns. It has been demonstrated that Epigenic Therapeutics’ platform, which combines a patented lipid nanoparticle (LNP) medicine delivery system, can accurately and effectively deliver medication to target cells and tissues both ex vivo and in vivo in models of ocular, neurodegenerative, metabolic, and rare diseases.

We try our  best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know

-if there are any discrepancies in any of our published stories,

-how we can improve,

-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by! 

Next Article

Previous articleNigeria-based Energy tech startup Beacon Power Services raises USD 2.7 million in seed funding
Next articleMiami-based sports betting firm Betr raises USD 50 million in Series A funding
Kshitij does business research and content writing for VCBay. Pursuing BBA from Symbiosis Center Of Management Studies (SCMS) Pune, he is skilled in Financial Modeling, Stock valuation and Microsoft Excel. He is passionate about Entrepreneurship and Finance.

LEAVE A REPLY

Please enter your comment!
Please enter your name here